GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chongqing Lummy Pharmaceutical (SZSE:300006) » Definitions » Interest Expense

Chongqing Lummy Pharmaceutical (SZSE:300006) Interest Expense : ¥-10.8 Mil (TTM As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Chongqing Lummy Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chongqing Lummy Pharmaceutical's interest expense for the three months ended in Sep. 2024 was ¥ -2.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-10.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chongqing Lummy Pharmaceutical's Operating Income for the three months ended in Sep. 2024 was ¥ -17.1 Mil. Chongqing Lummy Pharmaceutical's Interest Expense for the three months ended in Sep. 2024 was ¥ -2.9 Mil. Chongqing Lummy Pharmaceutical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chongqing Lummy Pharmaceutical Interest Expense Historical Data

The historical data trend for Chongqing Lummy Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Lummy Pharmaceutical Interest Expense Chart

Chongqing Lummy Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.33 -83.19 -32.08 -20.35 -12.47

Chongqing Lummy Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.99 -2.88 -2.57 -2.45 -2.88

Chongqing Lummy Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-10.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chongqing Lummy Pharmaceutical  (SZSE:300006) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chongqing Lummy Pharmaceutical's Interest Expense for the three months ended in Sep. 2024 was ¥-2.9 Mil. Its Operating Income for the three months ended in Sep. 2024 was ¥-17.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was ¥123.3 Mil.

Chongqing Lummy Pharmaceutical's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Chongqing Lummy Pharmaceutical did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Chongqing Lummy Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chongqing Lummy Pharmaceutical (SZSE:300006) » Definitions » Interest Expense
Comparable Companies
SZSE:301281 SHSE:600613 SZSE:002198 SZSE:001367 SZSE:000705 SZSE:000952 SZSE:000908 SZSE:000411 SZSE:300109 SHSE:688176 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
N/A
Address
99 Yuma Road, Nan'an District, chongqing, CHN, 401123
Website
http://www.cqlummy.com
Chongqing Lummy Pharmaceutical is a wholly-owned subsidiary of Lai America Pharmaceutical Co., Ltd. and is a professional pharmaceutical sales company in China.
Executives
Lai Wen Executives
Yuan Yuan Supervisors
Qiu Yu Directors, executives
Leng Xue Feng Secretary, Director
Zhang Xiao Xue Supervisors
Wang Ying Director
Zhou Xue Mei Supervisors
Zhao Bin Executives
Tang Xiao Hai Executives
Fu Rong Executives
Li Xian Feng Supervisors
Qiu Wei Director

Chongqing Lummy Pharmaceutical Headlines

No Headlines